Offering Buprenorphine Prior to Release from Jail May Reduce Recidivism

Findings from JCOIN’s Massachusetts Research Hub Individuals leaving incarceration with opioid use disorder (OUD) are at a high risk for overdose, recidivism, and adverse health outcomes. Providing medication for opioid use disorder (MOUD) prior to incarceration and post-release is effective in reducing negative outcomes. Existing studies tend to examine how the use of methadone and/or…

Read More

Massachusetts Justice Community Opioid Innovation Network (MassJCOIN)

The goal of this study is to conduct a Type 1 hybrid effectiveness-implementation study of seven jails in Massachusetts that deliver all FDA-approved MOUDs (naltrexone, buprenorphine, methadone) to produce findings with implications for policies for OUD in criminal justice settings. This research will focus on (1) post-release recidivism, overdoses, and MOUD initiation, engagement, and retention,…

Read More

Evaluation of Massachusetts Policy Mandating all Medication for Opioid Use Disorders in Jails (032)

A 2018 Massachusetts law (“Chapter 208”) established a 4-year pilot program to expand the use of all FDA-approved forms of medications for opioid use disorder (MOUD) at five county jails; two additional jails voluntarily joined this pilot. The law stipulates that MOUD be maintained in individuals who were already receiving it prior to detention; initiated prior to release from jail when appropriate; and continued in the community via facilitated linkages to local services after release. The Massachusetts Hub will conduct a longitudinal treatment outcome study of individuals in these jails to examine MOUD initiation, engagement and retention, as well as fatal and non-fatal overdose and recidivism. The study will also identify strategies associated with the successful implementation of MOUD and inform the development of future strategies to address opioid use disorder in jails nationwide.

Read More